✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Alendronate Sodium is a drug marketed by Hikma, Apotex, Aurobindo Pharma, Chartwell Rx, Cipla, Hangzhou Binjiang, Impax Labs Inc, Jubilant Cadista, Mylan, Picket Pharms, Rising, Sun Pharm, Teva Pharms, and Watson Labs. and is included in fourteen NDAs.
The generic ingredient in ALENDRONATE SODIUM is alendronate sodium. There are twenty-five drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the alendronate sodium profile page.
A generic version of ALENDRONATE SODIUM was approved as alendronate sodium by APOTEX on August 4th, 2008.
Summary for ALENDRONATE SODIUM
Recent Clinical Trials for ALENDRONATE SODIUM
Identify potential brand extensions & 505(b)(2) entrants
|Aristotle University Of Thessaloniki||Phase 4|
|424 General Military Hospital||Phase 4|
|Shanghai JMT-Bio Inc.||Phase 2|
Pharmacology for ALENDRONATE SODIUM
|Drug Class||Bisphosphonate |